Fezakinumab
N/A
Report date: 2024/01/02 20:03:52
Base Information
Drug NameFezakinumab
Drug Alias Name
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory +[14]
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A
Develop Information
Active CompaniesN/A
Inactive CompaniesWyeth LlcPfizer IncThe Rockefeller University
Active IndicationsN/A
Inactive Indications